Intranasal delivery specialist Impel NeuroPharma and the Toronto-based Centre for Addiction and Mental Health (CAMH) have signed a licensing agreement for an intranasal neuropeptide-based therapy for the treatment of depression. The peptide, which was discovered at CAMH, will be delivered using Impel's Precision Olfactory Delivery (POD) device. According to CAMH, … [Read more...] about Impel NeuroPharma licenses intranasal therapy for depression
Business
Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer
Inhaled drug developer Alexza Pharmaceuticals has signed a non-binding letter of intent and entered into discussions with Grupo Ferrer regarding Ferrer's acquisition offer, the company said. Alexza noted that the letter of intent allows the company to continue to explore other options, and there is no guarantee that it will complete the deal with Ferrer. In … [Read more...] about Alexza Pharmaceuticals signs non-binding letter of intent with Grupo Ferrer
MannKind founder Alfred Mann has died at age 90
MannKind Corporation has announced the death of founder and Chairman Emeritus Alfred Mann at age 90, one week after he stepped down as Chairman of the Board. Mann served as CEO from November 2003 until January 2015 and as Chairman of the Board of MannKind from 2001 until last week. According to the company, Mann's death will have no effect on business activities or … [Read more...] about MannKind founder Alfred Mann has died at age 90
Adapt launches Narcan nasal spray in the US
Adapt Pharma has announced the availability of Narcan naloxone hydrochloride nasal spray for the treatment of opioid overdose in the US. Narcan nasal spray was approved by the FDA in November 2015. In 17 of the 50 US states, no prescription is required. According to Adapt, the nasal spray will be available at a discounted price of $37.50 per dose for government … [Read more...] about Adapt launches Narcan nasal spray in the US
Teva Canada launches tobramycin inhalation solution
Health Canada has approved Teva Canada Limited's application for its tobramycin inhalation solution, a generic version of Novartis's TOBI inhalation solution for the treatment of P. aeruginosa infections in cystic fibrosis patients in Canada. The Teva tobramycin inhalation solution is now available in Canadian pharmacies, the company said. Teva Canada Limited … [Read more...] about Teva Canada launches tobramycin inhalation solution
Capsugel teams up with Pulmatrix on DPI development
Capsugel and Pulmatrix have announced an agreement for development of new inhaled therapies based on the spray drying and manufacturing expertise at Capsugel's Bend Research subsidiary combined with Pulmatrix's iSPERSE dry powder technology. Bend Research Head of Alliance Strategy Dan Dobry commented, “This strategic partnership with Pulmatrix puts our companies … [Read more...] about Capsugel teams up with Pulmatrix on DPI development
Meda to be acquired by Mylan
Mylan has announced that it will acquire Meda, which markets a number of OINDPs, including Dymista, Astelin, and Astepro nasal sprays; the Aerospan MDI; and the Novopulmon Novolizer and Formatris Novolizer DPIs. Meda had previously rejected acquisition by Mylan, but the Meda board now recommends that shareholders accept the offer, which is valued at SEK 60.3 billion … [Read more...] about Meda to be acquired by Mylan
Fraunhofer ITEM acquires Takeda inhaled surfactant technology
The Fraunhofer Institute for Toxicology and Experimental Medicine (ITEM) has acquired Takeda's Surfactant and Continuous Powder Aerosolization (CPA) program, the company said. According to the announcement, the transfer took place as Takeda shut down its respiratory department; Takeda sold its core respiratory business to AstraZeneca in December 2015. According … [Read more...] about Fraunhofer ITEM acquires Takeda inhaled surfactant technology
Rhinocort nasal spray now available over the counter in the US
Johnson & Johnson subsidiary McNeil Consumer Healthcare says that Rhinocort budesonide nasal spray is now available over the counter in the US for the treatment of allergic rhinitis. McNeil acquired the OTC rights to AstraZeneca's Rhinocort Aqua in 2014. McNeil Consumer Healthcare Group Brand Director Purvi Farahi commented, “For consumers who are suffering from … [Read more...] about Rhinocort nasal spray now available over the counter in the US
Septodont to promote Egalet’s Sprix nasal spray to US dentists
Egalet Corporation has announced that it has partnered with Septodont, Inc. to promote Sprix ketorolac tromethamine nasal spray to US dentists. Septodont will pay Egalet an undisclosed licensing fee up front, sales-based milestones and a share of profits from net sales. Sprix was approved by the FDA in 2010 for short-term treatment of moderate-to-severe pain. Its … [Read more...] about Septodont to promote Egalet’s Sprix nasal spray to US dentists